Department of Vascular and Endovascular Surgery, University Hospital Salzburg, Austria.
Department of Vascular and Endovascular Surgery, University Hospital Salzburg, Austria.
Eur J Vasc Endovasc Surg. 2019 Oct;58(4):556-563. doi: 10.1016/j.ejvs.2019.01.023. Epub 2019 Feb 26.
The small saphenous vein (SSV) is a potential vein source for bypass if neither greater saphenous vein nor arm vein is available. This study reports experience using SSV as part of an all autologous vein bypass policy.
This study comprised single centre retrospective data analysis of all consecutive patients treated at an academic tertiary referral centre from January 1998 to February 2017 using the SSV as the main peripheral bypass graft. Study endpoints were primary patency, secondary patency, limb salvage, and survival.
One hundred and twenty operations were performed in 118 patients using SSV. Indications were peripheral arterial occlusive disease (n = 91; Rutherford classification 3: n = 11; 4: n = 21; 5,6: n = 59), acute ischaemia (n = 14), popliteal artery aneurysm (n = 12), and bypass revisions (n = 3). Median follow up was 30.5 months (10 months-13.7 years). Primary patency after one, three and five years was 68% (CI: 59-77%), 58% (49-68%), and 54% (45-64%). Secondary patency was 83% (76-89%) after one year and 77% (69-85%) after three and five years. Limb salvage after one year was 88% (82-94%) and 78% (70-86%) after five years. Survival was 96% (92-99%) after one year and 91% (85-97%) at five years. Multivariable analysis identified redo surgery as an independent risk factor. Patients receiving a primary (n = 59) vs. a redo bypass (n = 61) were compared. Primary patency and secondary patency were both significantly better in the primary bypass group than in the redo group (p = .0036 and p = .0003, respectively). Limb salvage was also significantly better in primary bypass patients than in the redo group (p = .0007), whereas overall survival did not differ significantly (p = .48).
The SSV is a valuable alternative vein graft in peripheral bypass surgery. It achieves excellent long-term results, particularly in patients with primary procedures but also acceptable results in patients with redo surgery.
如果大隐静脉和上肢静脉都不可用,小隐静脉(SSV)是旁路移植的潜在静脉来源。本研究报告了在所有自体静脉旁路移植策略中使用 SSV 的经验。
本研究对 1998 年 1 月至 2017 年 2 月期间在一家学术性三级转诊中心接受 SSV 作为主要外周旁路移植物治疗的所有连续患者进行了单中心回顾性数据分析。研究终点为一期通畅率、二期通畅率、肢体存活率和生存率。
118 例患者共行 120 例手术,采用 SSV。适应证为外周动脉闭塞性疾病(n=91;Rutherford 分类 3:n=11;4:n=21;5、6:n=59)、急性缺血(n=14)、腘动脉动脉瘤(n=12)和旁路修复(n=3)。中位随访时间为 30.5 个月(10 个月至 13.7 年)。一年、三年和五年的一期通畅率分别为 68%(CI:59-77%)、58%(49-68%)和 54%(45-64%)。一年后二期通畅率为 83%(76-89%),三年和五年后为 77%(69-85%)。一年后肢体存活率为 88%(82-94%),五年后为 78%(70-86%)。一年后生存率为 96%(92-99%),五年后为 91%(85-97%)。多变量分析显示,再次手术是一个独立的危险因素。比较了接受初次旁路移植(n=59)和再次旁路移植(n=61)的患者。初次旁路移植组的一期通畅率和二期通畅率均显著优于再次旁路移植组(p=0.0036 和 p=0.0003)。初次旁路移植患者的肢体存活率也显著优于再次旁路移植组(p=0.0007),而总生存率无显著差异(p=0.48)。
SSV 是外周旁路手术中一种有价值的替代静脉移植物。它能获得优异的长期效果,尤其是在初次手术患者中,但在再次手术患者中也能获得可接受的效果。